Introduction
Polycyclic aromatic hydrocarbons (PAHs*) are found in the environment as products of incomplete combustion of fossil © Oxford University Press fuels (1). Carcinogenic PAHs are metabolically activated to electrophilic species (2) and covalent reaction of these with DNA is thought to be a critical event in the initiation stage of tumorigenesis (3) . Studies of over a dozen PAHs have either identified or implicated bay region diol-epoxides as ultimate carcinogenic metabolites (4) . Planar PAHs such as benzo [a] pyrene (B[a]P), benz [a] anthracene and chrysene form bay region diol-epoxides which bond almost exclusively with guanine bases in DNA. However, some PAHs have a sterically hindered bay region, causing a distortion from planarity of the parent molecule and thus of its bay region diol-epoxide derivative. An example is benzo[c]phenanthrene (B[c]Ph), whose bay region moiety is contained within a fjord region, formed by the fusion of four aromatic rings (5) (Figure 1 ). Studies have shown that the fjord region diol-epoxides of B[c]Ph (the B[c]PhDEs) are less ionic than planar equivalents and more reactive toward strong nucleophiles such as DNA, reacting with adenine as well as guanine bases (6) . The B[c]PhDEs also exhibit exceptionally high mutagenic activity in bacterial and mammalian cells (7) . Figure 2 ) is a pentacyclic PAH which occurs in coal tar and petroleum distillates (8) . Like B[c]Ph, it has a fjord region in its structure which renders the parent molecule non-planar. It has been shown that it is a moderate carcinogen on mouse skin (9) and when injected subcutaneously (10) . More recent studies have shown that the potential metabolites of B[g]C, the fjord region 11,12-diol-13,14-epoxides (B[g]CDEs), are highly mutagenic in bacterial and mammalian cells (11,12) and the racemic ann-diol-epoxide has been shown to be a mammary carcinogen in rats (13) . These diol-epoxides show extensive reactivity towards both adenine and guanine bases in DNA in in vitro studies (14, 15) .
Benzo[g]chrysene (B[g]C) (
Studies have shown that little of B[c]Ph is metabolically activated to its fjord region diol-epoxides in vivo, rendering the PAH only weakly carcinogenic (16, 17) . B[g]C on the other hand, is a moderate carcinogen and so it is postulated that there is significant metabolism to biologically active fjord region diol-epoxides in vivo. Figure 2 shows the proposed routes of metabolic activation of this PAH.
In our previous study (14) we examined, by 32 P-postlabelling, the reaction of the four individual fjord region diol-epoxides of B[g]C with DNA and distinguished between adducts formed with adenine and guanine. In the present study we have applied 
Materials and methods
Reagents and materials for 32 P-postlabelling were obtained from the suppliers mentioned previously (14) . HPLC grade methanol was purchased from BDH Ltd (Poole, Dorset, UK) and Zorbax phenyl-modified reversed phase columns from Hichrom (Reading, Berks, UK).
B[c]Ph was obtained from the Community Bureau of Reference (Brussels, fjord-region 
DNA isolation
The dermal surface of the frozen skin was scraped with a scalpel blade and the remaining frozen epidermal layer was powdered in liquid nitrogen (22) . The powdered skin samples were then thawed in 10 itiM EDTA and, after homogenization, a 10% solution of SDS (0.1 vol.) was added and the DNA isolated and purified using a previously published phenol extraction method (23).
Reaction of diol-epoxides with DNA, poly(dAdT) and poly(dGdC)
Aliquots (100 ul) of solutions of either DNA, poly(dGdC) or poly(dAdT) in 0.1 M Tris-HCl, pH 7.4, were mixed with solutions of the isomeric diolepoxides of B[g]C (10 ug) in THF/ethanol (1:8 v/v, 22.5 ul) as described previously (14) . The reaction mixtures were kept in the dark at room temperature overnight and then extracted with water-saturated diethyl ether (6X130 ul). The aqueous solutions were stored at -20°C prior to analysis.
P-Postlabelling analysis
Nuclease PI enhancement method. DNA samples from mouse skin (4 ug) were digested with micrococcal nuclease and spleen phosphodiesterase with further digestion with nuclease PI, as described previously (24) . Samples were then 32 P-labelled according to previously described methods (25) .
Standard method. DNA samples from in vitro treatments (I ug) were digested with micrococcal nuclease and spleen phosphodiesterase, as described previously (14) . Samples were then ^P-labelled using the postlabelling procedure essentially as described by Gupta el al. (25) .
Thin layer chromatography
Resolution of 32 P-labelled adducts was performed on polyethyleneimine (PEI)-cellulose TLC sheets (20X20 cm) using a four-directional anion exchange solvent system (25, 26) with the following solvents: Dl, 1.7 M sodium phosphate, pH 6.0; D2, 3.5 M lithium formate and 8.5 M urea, pH 3.5; D3, 0.8 M lithium chloride, 0.5 M Tris-HCl and 8.5 M urea, pH 8.0; D4, 1.7 M sodium phosphate, pH 6.0.
Adduct spots on the chromatograms were visualized by autoradiography at -70°C for 1 (in vitro samples) or 4 h (in vivo samples) using screen intensifies.
Quantitation of adducts
The adduct spots were excised from the chromatograms and levels of radioactivity determined by Cerenkov counting. Appropriate blank areas of the chromatogram were counted to obtain background levels, which were subtracted. The mean of the results of at least three 32 P-post-labelling experiments was determined in each case.
Standard method. The levels of adducts present were determined by relating the c.p.m. in normal nucleotides to the c.p.m. in adduct nucleotides as previously described (25) .
Nuclease PI enhancement method. The specific activity of [y- HPLC analysis HPLC analyses of adduct spots were carried out with the apparatus described by Pfau el al. (27) , consisting of two Waters 501 HPLC pumps, a Waters 712 WISP autosampler, a Waters 440 280 nm absorbance detector and a Berthold LB 507 HPLC radioactivity monitor. Gradient control and other data processing were achieved with Waters Baseline-810 software.
After quantilation on TLC adduct spots were eluted with pyridinium formate (4 M, pH 4.5, 500 ul) overnight and the eluates filtered and evaporated to dryness. The residues were redissolved in deionized water (100 |ll) before injection onto a Zorbax phenyl-modified reverse phase column (250X4.6 mm, particle size 5 nm). Elution was at a flow rate of 1.2 ml/min with the following solvent systems: 0-15 min, a linear gradient of 10-46% buffer B (methanol/ buffer A, 9:1) in buffer A (0.3 M sodium dihydrogen orthophosphate and 0.2 M orthophosphoric acid, adjusted to pH 2.0); 15-60 min, a linear gradient of 46-48% buffer B in buffer A; 60-80 min, a linear gradient of 48-80% buffer B in buffer A. Phenanthrene cis-9,10-diol was used as an internal marker, with a retention time of ~40 min.
Results
Formation and persistence of B/g]C-DNA adducts in mouse skin When digests of DNA from B[g]C-treated mouse skin were 32 P-postlabelled and chromatographed on 20X20 cm PEIcellulose TLC plates seven principle adduct spots were consistently detected ( Figure 3A) . Forty per cent of the radioactivity was contained in adduct spot e, while adduct spots b and / accounted for 27 and 20% respectively and the remaining four Mice were treated topically with 0.5 nmol of each compound. DNA was isolated and 32 P-postlabelled using the nuclease PI enhancement method as described in the text. Adducts were chromatographed on 20X20 cm TLC plates. The origin is located near the bottom left hand corner of each map and was excised prior to autoradiography, which was for 4 h at -70°C. Adduct spots are assigned letters based on their chromatographic mobilities. Co-chromatography experiments confirmed that adducts from different compounds designated by the same letter co-migrated on TLC.
spots accounted for between 2 and 5% each. All seven adduct spots could still be detected in mouse skin DNA 21 days after treatment.
The pattern of formation and removal of total B[g]C-DNA adducts in mouse skin is shown in Figure 4A . Maximum levels of 6.55 fmol adducts/(ig DNA were detected 24 h after treatment. There was a loss of 58% of the damage by day four, followed by a slower removal of adducts over subsequent days. Each adduct followed the same pattern of removal, as indicated in Figure 4B for three of the adducts, b, e and g. By 21 days 13% of the total damage remained.
DNA from mouse skin that had been treated with B[c]Ph was also analysed by 
Formation of DNA adducts by B[g]C-Jl,12-diols in mouse skin
When the DNA isolated from mouse skin that had been treated with (-)-or (+)-B[g]C-diol was hydrolysed and examined by 32 P-postlabelling the autoradiograms shown in Figure 3B and C respectively were obtained. Adduct spots have been assigned the same letters as those in Figure 3A , where they were found to co-migrate in TLC co-chromatography experiments. However, it should be borne in mind that stereochemical considerations dictate that (+)-and (-)-B[g]C-diols cannot form identical adducts and, indeed, in subsequent HPLC experiments some of these adducts assigned the same letter were found to be different, as described below. 
(-)-B[g]C-diol

) Total adduct levels (adducts a-g). (B) Individual adducts: A adduct b;
• adduct e; • adduct g.
gave an adduct pattern containing two major spots, spots b and e, accounting for 27.5 and 58% respectively of total radioactivity on the plate, and three minor adduct spots, lettered a, d and g. Twenty four hours after treatment of the skin the level of adduct formation by (-)-B[g]C-diol was 6.98 fmol adducts/(Xg DNA.
DNA from mouse skin that had been treated with (+)-B[g]C-diol gave a total of four adduct spots. Major adduct spots were spots c and/, accounting for 38 and 29% respectively of total radioactivity on the plate. A binding level of 1.43 fmol adducts/iig DNA was obtained 24 h after treatment, 5-fold lower than the level of adducts formed by (-)-B[g]C-diol.
Co-chromatography of 
HPLC analysis of the B[g]C-DNA adduct spots in mouse skin
Areas containing major adduct spots from postlabelled samples of DNA treated with B[g]C or one of the two B[g]C-diols were excised from the TLC plates and eluted. Aliquots of eluates of spots assigned the same letter, containing approximately the same level of radioactivity, were then examined both separately and together on HPLC. Table I gives the HPLC (Table I ). When these pairs of adducts were co-chromatographed they were found to co-elute. Adducts b and e, however, formed by (+)-B[g]C-diol ( Figure 3C ) did not elute on HPLC with similar retention times to adducts b and e formed by B[g]C ( Figure 3A ), as shown in Table I , despite the fact that these adducts co-migrated on TLC (see above). When mixed and co-chromatographed these pairs of adducts did not coelute. Figure 5A and B show the material from B[g]C-DNA adduct spot e and (-)-B[g]C-diol-DNA adduct spot e respectively, both eluting at ~40 min. Figure 5C shows coelution of these two adducts. Figure 5D shows the HPLC peak of material from (+)-B[g]C-diol-DNA adduct spot e, eluting at 37 min. Figure 5E shows co-chromatography of adducts e from Figure 3A and C and demonstrates that they do not coelute on HPLC. (Table I) .
Formation of B[g]CDE-DNA adducts in vitro
Solutions of the four B[g]CDEs were individually reacted with solutions of either DNA, poly(dGdC) or poly(dAdT). The modified nucleic acids were then digested and 32 P-postlabelled using the standard procedure and chromatographed on PEIcellulose plates. The TLC adduct maps arising from samples of DNA reacted with the B[#]CDEs are shown in Figure 6 . These adducts were identified as adenine or guanine adducts, as reported in our previous publication (14) , and this is indicated by a and g respectively after the adduct number in Figure 6 . Adduct spots formed in vitro which co-migrated on TLC with adduct spots formed in DNA from B[g]C-treated mouse skin were excised from the plates and chromatographed both singly and together on HPLC. B[g]C-DNA adduct spots a, b, d, e and g ( Figure 3A ) were found to co-elute with DNA adducts lg, 2g, 3g, 4a and 6a respectively formed by benzo Figure 6D ). Therefore, B[g]C adduct c is formed with guanine and adduct/is formed with adenine. Overall, three of the seven major adducts formed by B[g]C, accounting for 64% of the total radioactivity on the plate, were adducts formed with adenine bases. These results are summarized in Table II . 
) (-)-syn-B[g]CDE; (C) (+)-anti-V[g]CDE; (D) (+)-syn-B[g]CDE.
32 PPost-labelling was by the standard method. Autoradiography was for 1 h at -70°C. Adduct numbering is according to that previously published (14) . The additional letters indicate the DNA base with which the adduct was formed; a, adenine; g, guanine. 
(-)-an/i-B[£]CDE (-)-anti-B[g]CDE (+)-syn-B[g]CDE (-)-anti-B[g]CDE {-)-anti-B[g]CDE (+)-syn-B[g]CDE (~)-an!i-B[g]CDE
guanine guanine guanine guanine adenine adenine adenine a Adduct letters correspond to those in Figure 3A .
Discussion
In our previous study we demonstrated that all four fjord region B[g]CDEs are highly reactive towards DNA in vivo, reacting with both adenine and guanine residues.
Our present study has shown that only DNA adducts formed with ( As is the case with the diol-epoxide metabolites of other sterically hindered, and thus non-planar, PAHs, a high degree of reactivity towards adenine residues by the B[g]CDEs is seen, both in vitro and in vivo. Thus in mouse skin three out of the seven major B[g]C-DNA adducts detected were formed with adenine bases, accounting for 64% of the total radioactivity on the TLC plate ( Figure 3A) . In contrast, the four adducts formed with guanine bases in DNA accounted for only 36% of the total radioactivity detected on the plate. It has been postulated from studies of 7,12-dimethylbenz [a] anthracene that there is a strong association between PAH reactivity toward adenine in DNA and tumour initiating activity (30, 31) .
Metabolic Figure 3C ), two of which were identified as being adducts also formed by the parent compound. The remaining two adducts (b and e) did not co-elute on HPLC with the corresponding adducts derived from the parent compound, despite co-migrating with these adducts on TLC. This stresses the importance of using more than one chromatography system for this type of study, in order to establish the nature of DNA adducts. It is possible, however, that (+)-B[g]C-diol adducts b and e were formed during metabolism of the parent compound at levels below the limits of detection of our HPLC system and were not resolved on TLC from the more major adducts of the corresponding (-)-B[g]C-diol. A second possibility is that the DNA adducts from each of the B[g]C-l 1,12-diols are labelled with different efficiencies using the nuclease PI enhancement method of 32 P-postlabelling. However, we have demonstrated that these adducts are formed by the B[g]CDEs and, as reported in our previous study (14) , B[g]CDE-DNA adducts appear to label with equal efficiencies, as the same relative levels of adducts were detected by both the nuclease PI enhancement method and the standard method of 32 It should be noted that the previously published adduct retention times of the B[g]CDEs were normalized to a UV marker retention time of 40 min, whereas the retention times reported here in Table I have not been adjusted.
In summary, we have shown that B[g]C is metabolically activated in mouse skin to two fjord region diol-epoxides, the {-)-anti-and (+)-syn diol-epoxides. Each of these active metabolites is capable of forming DNA adducts with both guanine and adenine bases. Thus the pathways of activation of B[g]C in mouse skin are analogous to those of B[c]Ph in several metabolic systems. We have demonstrated the application of a combination of in vivo and in vitro systems and two chromatography methods to the elucidation of the pathway of metabolic activation of a PAH.
